Phase Ib/II Study of Efficacy and Safety of MEK162 and Panitumumab, in Adult mCRC Patients With Mutant or Wild-type RAS Tumors

Clinical trial NCT01927341 · COMPLETED

Trial details

NCT number

NCT01927341

Sponsor

Pfizer

Status

COMPLETED

Phase

Phase 1, Phase 2

Study type

INTERVENTIONAL

Start date

2013-11-19

Primary completion

2016-01-25

Enrollment

53

View on ClinicalTrials.gov